- Home
- COGT vs REPL Comparison
COGT vs REPL Comparison
Compare COGT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- REPL
- Stock Information
- Founded
- COGT 2014
- REPL 2015
- Country
- COGT United States
- REPL United States
- Employees
- COGT N/A
- REPL N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- COGT Health Care
- REPL Health Care
- Exchange
- COGT Nasdaq
- REPL Nasdaq
- Market Cap
- COGT 555.6M
- REPL 578.4M
- IPO Year
- COGT 2018
- REPL 2018
- Fundamental
- Price
- COGT $5.23
- REPL $9.80
- Analyst Decision
- COGT Buy
- REPL Strong Buy
- Analyst Count
- COGT 6
- REPL 6
- Target Price
- COGT $15.20
- REPL $20.00
- AVG Volume (30 Days)
- COGT 1.2M
- REPL 1.6M
- Earning Date
- COGT 05-06-2025
- REPL 05-22-2025
- Dividend Yield
- COGT N/A
- REPL N/A
- EPS Growth
- COGT N/A
- REPL N/A
- EPS
- COGT N/A
- REPL N/A
- Revenue
- COGT N/A
- REPL N/A
- Revenue This Year
- COGT N/A
- REPL N/A
- Revenue Next Year
- COGT N/A
- REPL N/A
- P/E Ratio
- COGT N/A
- REPL N/A
- Revenue Growth
- COGT N/A
- REPL N/A
- 52 Week Low
- COGT $3.72
- REPL $4.93
- 52 Week High
- COGT $12.61
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- COGT 60.43
- REPL 59.80
- Support Level
- COGT $4.80
- REPL $8.25
- Resistance Level
- COGT $4.99
- REPL $9.53
- Average True Range (ATR)
- COGT 0.34
- REPL 0.90
- MACD
- COGT 0.10
- REPL 0.21
- Stochastic Oscillator
- COGT 75.81
- REPL 90.11
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.